Press Room

12th Global Drug Delivery & Formulation Virtual Summit

Start
Monday, March 15, 2021 - 00:00
End
Wednesday, March 17, 2021 - 00:00
Location: online
Drug Delivery Formulation | Hovione

At Hovione we are constantly innovating to find better and more efficient ways of doing things.

Visit Hovione’s booth at the 12th Global Drug Delivery and Formulation Summit (DDF) and meet our team of experts.



Learn more about ASD-HIPROS – the most advanced and accurate screening platform able to identify the most efficient and stable Amorphous Solid Dispersion formulations by Spray Drying. Requiring as little as 5g of API and in just 6 weeks, this platform maximizes your chances of identifying a successful formulation, accelerating development towards commercial manufacturing and patient availability.

Schedule a meeting button | Hovione





Don’t miss our “Technology & Innovation” Session

Featured Speakers: Mafalda Paiva - Group Leader, R&D Analytical Development and João Henriques - Group Leader, R&D Drug Product Development

Title: Performance Enhancement Strategies for Low Solubility APIs – do more with less

Session Track: Technology & Innovation

Date: Wednesday, March 17, 2021

Time: 09:25AM – 10:00AM GMT

Abstract: The presentation will address the main challenges in the formulation of ASDs, highlighting the importance of integrated development and the synergies between pre-formulation and commercial manufacturing expertise. Mafalda and João will also be presenting ASD HIPROS, our new state-of-the-art, science-based development platform for ASDs.

Conference Website: httpss://www.ddfevent.com/ 

12th Global Drug Delivery & Formulation Virtual Summit | Hovione

 

 

Interested in turning your most difficult challenge into a successful solution?

 

 

Schedule a meeting with our experts

 





 

You might be interested in:









 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026